Short Interest in 23andMe Holding Co. (NASDAQ:ME) Decreases By 16.6%

23andMe Holding Co. (NASDAQ:ME) was the recipient of a large decline in short interest during the month of November. As of November 30th, there was short interest totalling 950,200 shares, a decline of 16.6% from the November 15th total of 1,140,000 shares. Based on an average daily trading volume, of 325,600 shares, the short-interest ratio is presently 2.9 days. Approximately 5.9% of the shares of the company are short sold.

23andMe Price Performance

Shares of NASDAQ:ME opened at $3.35 on Friday. 23andMe has a 1 year low of $2.65 and a 1 year high of $20.40. The company has a market capitalization of $87.50 million, a PE ratio of -0.13 and a beta of 1.15. The business has a fifty day moving average price of $4.33 and a two-hundred day moving average price of $6.58.

23andMe (NASDAQ:ME) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($2.32) earnings per share for the quarter. The company had revenue of $44.07 million for the quarter, compared to the consensus estimate of $50.30 million. 23andMe had a negative net margin of 318.39% and a negative return on equity of 129.98%.

Institutional Investors Weigh In On 23andMe

Several large investors have recently modified their holdings of ME. Levin Capital Strategies L.P. purchased a new stake in 23andMe during the second quarter valued at about $61,000. Vanguard Personalized Indexing Management LLC raised its position in shares of 23andMe by 410.4% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 88,555 shares of the company’s stock valued at $35,000 after purchasing an additional 71,204 shares during the period. Point72 DIFC Ltd purchased a new stake in shares of 23andMe during the 2nd quarter valued at approximately $43,000. Point72 Asia Singapore Pte. Ltd. bought a new position in 23andMe in the 2nd quarter worth approximately $203,000. Finally, AQR Capital Management LLC grew its stake in 23andMe by 145.8% in the 2nd quarter. AQR Capital Management LLC now owns 444,222 shares of the company’s stock valued at $174,000 after buying an additional 263,468 shares in the last quarter. Hedge funds and other institutional investors own 36.10% of the company’s stock.

23andMe Company Profile

23andMe Holding Co operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications.